No change in small low-density lipoprotein cholesterol levels with pemafibrate might explain the negative results of the PROMINENT trial

J Diabetes Investig. 2023 Apr;14(4):630-631. doi: 10.1111/jdi.13983. Epub 2023 Jan 27.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Cholesterol
  • Cholesterol, HDL
  • Humans
  • Hypolipidemic Agents*
  • Lipoproteins, LDL
  • Negative Results*
  • Triglycerides

Substances

  • (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid
  • Hypolipidemic Agents
  • Cholesterol
  • Lipoproteins, LDL
  • Cholesterol, HDL
  • Triglycerides